semaglutide · GLP-1 receptor agonist
Oral Wegovy
Preserves the split between PI, live-site, and approval-headline tablet claims.
Live fetch
Efficacy anchors
0 anchors
No efficacy anchors are available for this product.
Price anchors
2 anchors
Starting self-pay
IntroDose context: 1.5 mg
Program: NovoCare self-pay program
Why this number?
Limited-time new patient offer. Offer end: August 31, 2026
Self-pay new-patient program pricing
Patient segment: cash_pay_new_patient
Limited-time new patient offer
Maintenance self-pay
MaintenanceDose context: 9 mg
Program: NovoCare self-pay program
Why this number?
Standard self-pay program pricing
Patient segment: cash_pay
Source ledger
1 linked
backs: Starting self-pay, Maintenance self-pay
Timeline
Change history
No change events are available for this product yet.